Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Neurocrine Biosciences Inc (NBIX) vs Raymond James Financial, Inc. (RJF) Price & Performance

Neurocrine Biosciences IncTrade
Raymond James Financial, Inc.Trade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs Raymond James Financial, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while Raymond James Financial, Inc. trades at $168.25 (market cap $32.80B). The key difference: Raymond James Financial, Inc. is the larger of the two by market cap, and Raymond James Financial, Inc. pays a 1.28% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

NBIXRJF
Market Cap
$17.40B$32.80B
Sector
HealthFinancials
52-Week High
$180.55$176.43
52-Week Low
$123.10$140.89
Enterprise Value
$16.49B
Dividend Yield
1.28%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX

About Raymond James Financial, Inc.

Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.

Read more on RJF